Key facts
- This page summarizes Richard Scott Struthers's Form 4 filing for Crinetics Pharmaceuticals, Inc. (CRNX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 25 Feb 2026, 16:37.
Richard Scott Struthers - 23 Feb 2026 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)
- Reporting relationship
- President & CEO, Director
- Issuer ticker
- CRNX
- Reported as of
- 23 Feb 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 25 Feb 2026, 16:37:01 UTC
- Prior SEC filing
- 18 Dec 2025
- Next SEC filing
- 18 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Tobin Schilke, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Richard Scott Struthers filed Form 4 for Crinetics Pharmaceuticals, Inc. (CRNX) on 25 Feb 2026.
Change
- Previous filing in this sequence was filed on 18 Dec 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001746298
Primary reporting owner
Struthers Richard Scott
- Relationship
- President & CEO, Director
- Address
- C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO
- Signature
- /s/ Tobin Schilke, as attorney-in-fact
- Signature date
- 25 Feb 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CRNX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +62,000
- Change %
- +17%
- Price
- $0.000000
- Shares after
- 426,759
- Date
- 23 Feb 2026
- Ownership
- Direct
- Footnotes
- F1
CRNX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 661,205
- Date
- 23 Feb 2026
- Ownership
- By Family Trust 1
CRNX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 106,000
- Date
- 23 Feb 2026
- Ownership
- By Family Trust 2
CRNX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 110,000
- Date
- 23 Feb 2026
- Ownership
- By Family Trust 3
CRNX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 100,000
- Date
- 23 Feb 2026
- Ownership
- By Family Trust 4
CRNX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,000
- Date
- 23 Feb 2026
- Ownership
- By Spouse
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CRNX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +228,000
- Change %
- Price
- $0.000000
- Shares after
- 228,000
- Date
- 23 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 228,000
- Exercise price
- $43.79
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2027.
Footnote F2
The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 23, 2026.